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INTRODUCTION
Physical injury to the skin triggers a
well-coordinated series of events leading
to wound closure. Wound healing occurs
in three phases: inflammation, prolifera-
tion and remodeling. The inflammatory
phase involves hemostatic activation
(vasoconstriction, platelet aggregation
and clot formation), vasodilation, in-
flammatory cell migration, phagocytosis
and production of inflammatory media-
tors. In the proliferative phase, granula-
tion tissue is formed, wound edges con-
tract and epithelial cells migrate to cover
the wound surface. During remodeling,
tissue structure is reorganized to most
closely resemble normal skin. This phase
involves disappearance of the majority
of inflammatory cells, deposition and
maturation of proteoglycans and colla-
gens replacing transient matrix ele-
ments. Many soluble factors such as in-
flammatory cytokines (tumor necrosis
factor [TNF]-α, interleukin [IL]-1β, IL-6)
and chemokines, growth factors
(platelet-derived growth factor [PDGF],
epidermal growth factor [EGF], fibrob-
last growth factor [FGF], transforming
growth factor [TGF]β, keratinocyte
growth factor [KGF7]) have been shown
to regulate the wound healing process
(1). Moreover, reactive oxygen and nitro-
gen species (ROS and RNS, respectively)
are also abundantly produced during
wound healing and regulate various as-
pects of the process (2).
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Understanding complex regulatory cir-
cuitries operating in normal or patholog-
ical wound healing is of utmost impor-
tance for the successful treatment of
wound healing abnormalities. These in-
clude impaired wound healing in dia-
betes, systemic sclerosis or chronic leg
 ulcers.
The treatment of chronic, nonhealing
wounds represents a major health issue
with treatment costs estimated to amount
to 25 billion USD per year in the United
States alone (3). Current modern or ex-
perimental treatments include dressings
impregnated with collagenase, DNase,
PDGF or nitric oxide-releasing com-
pounds. In spite of the high number of
novel and innovative approaches to cure
nonhealing wounds, the efficient treat-
ment of these diseases still represents an
unmet medical need.
On the basis of available literature,
PARylation appeared to be a likely candi-
date for being a regulator of the wound
healing process (see below). PARylation is
a covalent protein modification carried
out by poly(ADP-ribose) polymerase
(PARP) enzymes. PARPs cleave off nicoti-
namide from NAD+ and attach the re-
maining ADP-ribose moieties to suitable
protein acceptors. By cleaving many NAD+
molecules and adding further ADP-ribose
units to the protein-proximal first residue,
these enzymes build a large, branched
poly(ADP-ribose) (PAR) polymer on pro-
teins. The polymer is degraded mostly by
PAR glycohydrolase (PARG). PARP-1, -2
and -3 are DNA-damage–sensitive en-
zymes that become activated by DNA
breaks. For example PARP-1, the main
PARP enzyme, has been shown to become
activated by oxidative stress-induced
DNA damage and to facilitate DNA break
repair. Moreover, PARP-1 is a cofactor of
nuclear factor (NF)-κB, the master regula-
tor of the transcription of inflammatory
mediators. PARylation also regulates a
wide variety of molecular events and cel-
lular functions including genome organi-
zation, replication, protein stability and
cell death.
On the basis of the involvement of
many of these PARylation-related reac-
tions (oxidative stress response, expres-
sion of inflammatory cytokines and
chemokines, cell proliferation and mi-
gration) in the wound healing process,
we set out to investigate the role of
PARylation in a mouse model of excision
wounding.
MATERIALS AND METHODS
Animals
Animal experiments were approved by
the Institutional Animal Care and Use
Committee of University of Debrecen
(protocol number 9/2008/DEMÁB) and
were carried out in accordance with the
EU guidelines on animal protection (4).
Adult male BALB/c mice (6 to 8 wks
old) were used for assessing the effect of
the PARP inhibitors 3-aminobenzamide
(3-AB) and PJ34 (Sigma-Aldrich, St. Louis,
MO, USA) on wound closure. In addi-
tion, male (6 to 8 wks old) homozygous
PARP-1 knockout mice (PARP-1–) and
their respective wild-type (PARP-1+/+) lit-
termates (5) were also used. All animals
were housed individually under con-
trolled conditions with 12-h light–dark
cycle, and were allowed free access to
water and diet.
Wound Healing Model
Wound incision was performed as de-
scribed previously in (6). Mice were
anaesthetized with isoflurane (Abbott
Animal Health, Abbott Park, IL, USA).
The fur was removed from the back of
mice by applying a commercial depila-
tory cream and hairless skin was wiped
with 70% ethanol. Mice were kept warm
during anesthesia and surgery using a
heat lamp. Two full thickness 4 mm
punch biopsies were made on the dorsal
surface of BALB/c mice and the wound
beds were wiped with povidone-iodine
to prevent infection. The PARP inhibitors
PJ-34 and 3-aminobenzamide (3-AB)
were applied locally on one of the
wounds in hydrophilic cream in
100 μmol/L and 50 μmol/L concentra-
tions, respectively. The control wound
was treated with hydrophilic cream only.
Treatments were repeated daily for 7 d
and wounds were covered with a surgi-
cal dressing to keep the cream in place.
Wounding and treatments of PARP-1–/–
and PARP-1+/+ mice (n = 6 for each geno-
type) was performed the same way as
detailed above.
Quantification of Wound Closure
Wounds from individual mice were
digitally photographed daily for 7 d. All
photographs were taken from an angle
perpendicular to the wound with a sterile
ruler placed adjacent to the wounds for
standardization (7). The wound area was
quantified using NIH ImageJ software
(NIH, Bethesda, MD, USA); and wound
closure was expressed as the ratio of ac-
tual wound area to initial wound size.
Tissue Harvesting
Tissue samples were collected from a
separate cohort of mice (n = 6 per time
point) on d 0, 1, 2, 4 and 8 after wound-
ing. Under isoflurane anesthesia, wound
tissue was harvested using a circular
blade (6 mm). After wounds had been
collected, animals were euthanized. One
of the two wound samples in each ani-
mal was processed for histology while
the other was snap frozen in liquid nitro-
gen for RNA and protein analysis (8).
Histological Examination
PAR was detected by immunostaining
as formerly described in (9). In brief, im-
munofluorescent staining was performed
on formalin-fixed skin tissues by use of a
PAR-specific monoclonal antibody (clone
10H; Enzo Life Sciences, Farmingdale,
NY, USA) and a  fluorescein-based mouse-
on-mouse Immunodetection kit (Vector
Laboratories, Peterborough, UK). Nuclei
were counterstained with DAPI (Invitro-
gen, Life Technologies [Thermo Fisher
Scientific Inc., Waltham, MA, USA]); and
stainings were visualized with a Zeiss
Axiolab fluorescent microscope.
RNA Extraction and Real-Time
Quantitative PCR Analysis (RT-qPCR)
RT-qPCR was carried out as described
in (10). In brief, total RNA from frozen
skin tissue was isolated with TRIzol
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reagent (Invitrogen, Life Technologies
[Thermo Fisher Scientific Inc.]) accord-
ing to the manufacturer’s instructions.
The concentration of isolated RNA was
determined spectrophotometrically and
finally adjusted to 2 μg for the reverse
transcription (RT) step. By use of a high
capacity-RT kit (Applied Biosystems
[Thermo Fisher Scientific Inc.]), RT was
performed in a mixture of 2 μL RT
buffer, 0.8 μL dNTP, 2 μL random
primer, 1 μL reverse transcriptase and
diethylpyrocarbonate (DEPC) H2O up to
10 μL. PCR cycles (Veriti 96-Well Ther-
mal Cycler, Thermo Fisher Scientific
Inc.) were set as follows: 25°C for
10 min, 42°C for 60 min, 95°C for 5 min,
94°C for 5 min, followed by 35 cycles
94°C for 30 s, 67°C for 1 min and 74°C
for 1 min. SYBR Green (Applied Biosys-
tems [Thermo Fisher Scientific Inc.])
qPCR reactions were run in ABI 7500
thermal cycler (Applied Biosystems
[Thermo Fisher Scientific Inc.]). Se-
quences of primers are given in Supple-
mentary Table 1. Expression values were
normalized to the control gene glycer-
aldehyde 3-phosphate dehydrogenase
(GAPDH) expression.
Western Blot Analysis
The method of lysate preparation and
immunoblotting was carried out as previ-
ously reported by Kioka et al. (11). Briefly,
frozen skin tissue (approximately 5 mg)
was homogenized in 300 μL RIPA buffer
(20 mmol/L Tris-HCL pH7.4, 150 mmol/L
NaCl, 1 mmol/L EDTA, 1%  Triton-X100,
1% sodium deoxycholate, 0.1% SDS) with
PMSF (1 mmol/L) and protease inhibitor
cocktail (5 mmol/L) added immediately
before use. Protein concentrations were
determined using BCA kit (Pierce, Rock-
ford, IL, USA).  Proteins were separated
on 8% SDS- polyacrylamide gels, and then
transferred onto nitrocellulose mem-
branes. Nonspecific protein binding was
blocked by incubating the membranes in
5% w/v BSA in Tris-buffered saline with
Tween® 20 (TBS-T; 50 mmol/L Tris-HCl,
pH 7.6, 150 mmol/L NaCl, and 0.1% v/v
Tween-20). Membranes were incubated
overnight at 4°C with mouse monoclonal
anti-nitrotyrosine antibody (Cayman,
Ann Arbor, MI, USA) or rabbit polyclonal
anti-FGF antibody (Abcam, Cambridge,
UK) at dilutions of 1:1000 and 1:500, re-
spectively. After washes, membranes
were incubated with either HRP-conju-
gated anti-mouse or anti- rabbit antibody
at a dilution of 1:10,000 for 1 h at room
temperature. Detection of mouse mono-
clonal β-actin (Sigma-Aldrich) (1:5000 di-
lution, 1-h–room- emperature incubation)
served for normalization. Protein bands
were detected using the ECL Plus kit
(Pierce) and densitometry was carried
out using NIH ImageJ software.
Scratch Assay
Confluent cultures of primary human
keratinocytes seeded in 96-well plates
were scratched with a small pipette tip
utilizing a Tecan Freedom EVO liquid
handling robot (Tecan Group Ltd.,
Männedorf, Switzerland). Damaged cells
were removed by washing with PBS so-
lution. A triplicate of freshly wounded
samples was dried and used as control
(0% healed samples). Cells were treated
with PJ-34 or 3-AB and incubated for
48 h. Cell culture medium was replaced
with Coomassie staining solution and
cells were stained for 20 min. Samples
were then washed twice with PBS and
photos were taken under a Zeiss 
AxioVision microscope (Carl Zeiss Mi-
croscopy GmbH, Jena, Germany). Images
were analyzed with Tscratch software.
Ratio of covered area was compared
with freshly wounded samples.
Statistical Analysis
All values are presented as means ±
SEM. Statistical analysis of experimental
data was performed with one-way analy-
sis of variance (ANOVA), followed by
Dunnett test for multiple comparisons.
Results were considered statistically sig-
nificant when p < 0.05.
All supplementary materials are available
online at www.molmed.org.
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Figure 1. Two full thickness cutaneous wounds (4-mm diameter) were made on the back of
male BALB/c mice, and wounds were evaluated by daily digital photography. Wounds were
treated topically with either vehicle (hydrophilic cream, left wound) or PJ34 (100 μmol/L in
hydrophilic cream; right wound) for 7 consecutive d; starting 24 h after excision. The line
graph represents the mean of percent change relative to original wound size ± SEM (n = 8).
*P < 0.05, **P < 0.01, ***P < 0.001: significantly different as compared between PJ34-treated
(solid line) and vehicle-treated (dashed line) wounds in the same time point.
RESULTS
To investigate the role of PARylation in
wound healing, we set up a mouse
model of excision wounding with two
wounds made on the back of each mice.
One of the wounds on each mouse was
treated with a hydrophilic crème
whereas the other wound was covered
with hydrophilic crème containing the
PARP inhibitor 3-AB (50 μmol/L). We
followed wound closure with time and
found that 3-AB significantly accelerated
the closure of wounds (Figure 1).
To confirm our results obtained with 
3-AB, we also applied another PARP in-
hibitor, PJ-34. Similarly to 3-AB, the ap-
plication of PJ-34 has also stimulated the
wound-healing process (Figure 2).
Since PARP-1 is responsible for the
bulk of PAR synthesis in oxidative stress
situations such as wound healing, we hy-
pothesized that the effects of PARP in-
hibitors is mainly due to inhibition of
PARP-1. Indeed wounds on PARP-1
knockout animals healed faster than
wounds on wild-type mice (Figure 3), con-
firming that activation of PARP-1 leads to
delayed wound healing. Expression of
PARP-1 mRNA increased between d 0
and d 4, but declined by d 8 (Figure 4A).
Basal expression of PARP-2 was much
lower than that of PARP-1, and it also
showed a moderate increase up to d 4
(Figure 4B). PARylation, however, is not
primarily regulated at the expression
level but mostly at the activity level. Ap-
pearance of PAR, the product of PARP-
catalyzed reaction in the woundbed (Fig-
ure 4C) indicates that PARylation indeed
takes place during wound healing.
Inflammation is an essential phenome-
non accompanying the wound healing
process. Excision wounding triggered the
expression of various inflammatory me-
diators such as IL-1β, TNF-α, IL-6, cy-
clooxygenase-2 (COX-2) and inducible ni-
tric oxide synthase (iNOS) (Figure 5A–E).
PARP-1 deficiency affected the expres-
sion of genes encoding most of these in-
flammatory mediators with the most sig-
nificant reduction seen in IL-6, TNF-α
and iNOS expression. Production of
much nitric oxide may lead to the forma-
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Figure 3. Full thickness cutaneous wounds (4-mm diameter) were made on the back of
male PARP-1–/– and wild-type control mice and wounds were evaluated by daily digital
photography. Wound areas (percentage of original wound area) are presented as mean ±
SEM (n = 6 for each group). (*P < 0.05)
Figure 2. Two full thickness cutaneous wounds (4-mm diameter) were made on the back of
male BALB/c mice and wounds were evaluated by daily digital photography. Wounds were
treated topically with either vehicle (hydrophilic cream, left wound) or 3-AB (50 μmol/L in
hydrophilic cream; right wound) for 7 consecutive days; starting 24 h after excision. Each
time point represents mean of eight measurements ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001)
tion of peroxynitrite, a powerful protein-
nitrating agent. Protein nitration was
most prominent on a 57-kDa protein of
the wound homogenate. Consistent with
lower iNOS expression in PARP-1
knockout mice, the intensity of tyrosine
nitration was also lower in the wound
lysates of PARP-1-deficient animals (Fig-
ure 5F).
Matrix metalloproteinases (MMPs) and
their tissue inhibitors (TIMPs) also play
important roles in wound healing (12).
We have determined the expression of
MMP-9, TIMP-1 and TIMP-2 mRNA in
homogenates of wounds from wild-type
and PARP-1 knockout mice. Expression
of MMP-9, TIMP-1 and -2 increased until
d 4 but declined by d 8 (Supplementary
Figure S1). The expression profile of
TIMP-2 in PARP-1 knockout mice did
not significantly differ from that of wild-
type mice. However, expression of MMP-
9 on d 1 and d 4 was significantly lower
in the PARP-1-deficient animals, whereas
the expression of TIMP-1 in PARP-1
knockout mice was lower only on d 4.
Proliferation and migration of fibrob-
lasts as well as keratinocytes is important
for granulation tissue formation and ep-
ithelialization. In in vitro scratch assays,
inhibition of PARylation by either 
3-aminobenzamide or PJ-34 facilitated
migration of primary human keratino -
cytes and thus the repopulation of the
scratched surface (Figure 6).
DISCUSSION
The wound-healing process requires a
precisely orchestrated series of tightly
controlled cellular events and it has four
main phases: hemostasis, inflammation,
proliferation and remodeling. Any dis-
ease condition (for example, diabetes,
circulatory problems) or external factor
(for example, cytostatic drugs) disturbing
this highly complex process may lead to
the development of chronic nonhealing
wounds. On the basis of the pleiotropic
biological functions of PARylation by
PARP-1 we hypothesized that it may reg-
ulate wound healing. Our main finding
is that PARP-1 activity slows down the
wound-healing process. Both the PARP-1
knockout phenotype and treatment with
PARP inhibitors accelerated the healing
of incision wounds. Accompanying ac-
celerated wound healing, a suppression
of inflammatory cytokines (IL-1β, TNF-α,
IL-6), COX-2, MMP-9 and iNOS could
also be observed. The somewhat surpris-
ing finding of accelerated wound healing
upon genetic inactivation of the parp-1
gene or inhibition of PARP activity can
be due to a combination of effects on var-
ious cellular events required for wound
healing as discussed below.
One possible explanation underlying
the stimulatory effect of PARP inhibition
or PARP-1 deficiency may be improved
cell metabolism or maintenance of gen-
eral cellular “health.” It has been demon-
strated in a high number of cellular and
animal models characterized by oxida-
tive stress that PARP-1 becomes acti-
vated by DNA breakage caused by ROS
and RNS (13). Intense or sustained
PARP-1 activation may lead to a compro-
mised cellular energetic state due to de-
pletion of NAD (the substrate of PARPs)
and ATP. Compromised cellular energet-
ics may lead to cell dysfunction or even
to (necroptotic) cell death (14). One plau-
sible hypothesis explaining our current
findings is that PARP-1-mediated cell
dysfunction may disturb the complex
network of wound healing regulation.
ROS-induced keratinocyte or fibroblast
injury has been repeatedly demonstrated
to occur via PARP activation (15–17), and
it cannot be excluded that this pathway
also operates in excision wounds. In fact,
detection of PAR polymer in the wound
bed (Figure 4C) illustrates that this might
indeed be the case. Slowing down
wound healing by PARP activation may
even serve a good purpose: considering
the role of PARylation in single strand
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Figure 4. Relative expression of (A) PARP-1/GAPDH mRNA (in PARP-1+/+mice), (B) PARP-2/
GAPDH mRNA (in PARP-1+/+ and PARP-1–/– mice) were determined from wound tissue sam-
ples using RT-qPCR at different time points. Error bars represent SEM of six independent
samples. (**P < 0.01). (C) Immunofluorescent staining of formalin-fixed, paraffin-embedded
skin tissues (wound beds) for PAR formation (green). Nuclei were counterstained with DAPI
(blue).
break sensing (and consequently repair)
it may slow down cell proliferation (re-
quired for granulation tissue formation
and epithelialization) and thus provide a
sufficient amount of time for the DNA
repair machinery to restore the integrity
of DNA.
Another interesting possibility is that
a suppressed inflammatory response in
PARP-1 knockout animals or in PARP in-
hibitor-treated mice may result in accel-
erated wound healing. The role of in-
flammation in wound healing is
somewhat controversial but most reports
underline the beneficial effects of antiin-
flammatory therapies. One common fea-
ture of most nonhealing wounds is per-
sistent inflammation which is mostly
due to macrophage dysregulation lead-
ing to an M1 dominated (inflammatory)
phenotype over M2 (wound healing)
phenotype (18). Moreover, application of
mesenchymal stem cells, a type of multi-
potent stem cells with a strong antiin-
flammatory effect has been shown re-
peatedly to improve wound healing
(19–21). Furthermore, scarless fetal
wound healing is also characterized by a
reduced inflammatory response (22), in-
dicating that inflammation affects not
only the dynamics but also the quality of
wound healing.
Our finding that expression levels of
TNF-α and, to a lesser extent, IL-1β is
lower in PARP-1 knockout mice may be
one of the factors underlying improved
wound healing. It has been suggested
that targeting these two inflammatory
cytokines may be beneficial for the
wound healing process. For example
Mori et al. (23) reported accelerated
wound healing in TNF receptor–deficient
mice. Moreover, Infliximab, a chimeric
monoclonal antibody against TNF-α
used to treat autoimmune diseases, has
been found to improve healing of
chronic wounds (24). Interestingly, de-
spite promising opportunities, the thera-
peutic potential of targeting IL-1β in 
inflammatory conditions (for example,
autoimmune diseases) has not yet been
explored in such a detail as for TNF-α.
As for wound healing, it has been re-
ported that disruption of IL-1β signaling
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Figure 5. Expression of inflammatory cytokines (A–C), iNOS (D) and COX-2 (E) were quantified using RT-qPCR. Expression values were nor-
malized to GAPDH. (F) Immunoblot analysis of nitrotyrosine in PARP-1+/+ and PARP-1–/– mice. All blots were normalized β-actin. Values are
expressed as mean ± SEM. (n = 6). (*P < 0.05, **P < 0.01, ***P < 0.001)
by knocking out IL-1 receptor type I im-
proved the quality of wound healing
(lower levels of collagen and improved
restoration of normal skin architecture)
identifying IL-1β signaling as a potential
target in wound healing (25). Moreover,
blocking the Nod-like receptor protein 3
(NLRP-3)–caspase-1–IL-1β pathway also
was demonstrated to improve wound
healing in diabetic mice (18). Of note, ex-
pression of IL-1β in our current model
did not differ very much between wild-
type and PARP-1-knockout animals, sug-
gesting that IL-1β is not the main factor
contributing to the effects of PARP-1 in-
hibition/knockout in this model.
IL-6, the level of which also was found
to be lower in PARP-1 knockout mice
(Figure 5), is also considered as a key in-
flammatory cytokine. However, its role
in wound healing appears to be opposite
to those of TNF-α or IL-1β. For example,
treatment with IL-6 augmented wound
healing in immunosuppressed mice (26).
In line with this, Lin et al. (27) reported
delayed wound healing in IL-6-deficient
mice. Thus, reduced IL-6 levels are not
likely to explain accelerated wound heal-
ing in PARP-1-deficient mice.
Here we also report reduced expres-
sion of iNOS in the wounds of PARP-1-
deficient mice. Expression of iNOS is re-
garded as a general feature of the
inflammatory response. Its role in
wound healing, however, appears to be
controversial with iNOS deficiency re-
ported to either delay (28) or have no ef-
fect on wound healing (29) depending
on the type of wounds investigated. Im-
paired collagen accumulation also has
been observed in iNOS-deficient mice
(30), further strengthening the hypothe-
sis that iNOS regulates wound healing.
Nitration of proteins also was found to
occur in the wound tissue with nitration
of an unknown 57-kDa protein being less
intense in the PARP-1-deficient tissue
(see Figure 5.). PARP inhibition or PARP-1
deficiency have been shown to reduce
both oxidative and nitrative stress in dif-
ferent animal models of tissue injury
and inflammation ranging from arthritis
to sepsis, ischemia-reperfusion or burn
injury (13,31). Nitric oxide (NO) and su-
peroxide need to be produced in near
equimolar amounts to form peroxyni-
trite, one of the most prominent nitrat-
ing agents. PARP inhibition has been
shown to reduce production of both NO
and ROS in various diverse models of
tissue injury and inflammation and this
was shown to result in suppressed nitra-
tion of proteins, lipids and DNA (13).
Decreased ROS production may also
suppress activation of NF-κB, the master
regulator of the transcription of inflam-
matory mediators which may culminate
in reduced production of inflammatory
cytokines and chemokines (see above).
Protein–protein interaction between 
NF-κB and PARP-1 also may be impor-
tant, but direct stimulation of NF-κB by
PARP-1 may only be relevant in PARP-1-
deficient animals, but not in mice treated
with PARP inhibitors since the interac-
tion between these two proteins does
not require PARP-1 activity (32).
Matrix metalloproteinases (MMPs) are
also important, especially in the remod-
eling phase of wound healing. Here we
found reduced expression of MMP-9 in
the wounds of PARP-1-deficient mice
and expression of some TIMPs was also
dysregulated, but to a lower extent. In
line with our finding, Kauppinen and
Swanson also reported (33) that PARP in-
hibition suppressed MMP-9 expression
in TNF-α-stimulated microglia cells. In-
creased MMP9 has been suggested to
predict poor wound healing in diabetic
foot ulcers (34). Therefore, we think it is
possible that suppressed MMP-9 expres-
sion may have contributed to accelerated
wound healing in PARP-1 deficient mice.
An interesting finding in our current
paper was that keratinocytes migrated
faster in the presence of a PARP in-
hibitor. Repopulation of the scratched
area requires both proliferation and cell
migration. The role of PARP-1/PARyla-
tion in cell proliferation is somewhat
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Figure 6. PARP inhibition stimulates keratinocyte migration. Confluent cultures of keratinocytes
were scratched with a pipette tip fixed to a liquid handling robot arm followed by washing
and incubation of cells with medium (control), with PJ-34 (10 μmol/L) or 3-AB (3 mmol/L). 
Microphotographs were taken after 48 h. Representative images are presented (top) and
repopulation of the scratched areas also was quantified by image analysis.
controversial. On the one hand, PARP-1
has been shown to be part of the multi-
protein replication complex (35) while on
the other hand various studies identified
it as an inhibitor of replication (36) and a
negative regulator of cell proliferation
(37). Its role in cell migration has not yet
been systematically investigated. Thus
identifying critical molecular control
points of accelerated proliferation/mi-
gration of PARP-inhibited cells requires
further investigation.
We should note a limitation of our
study: while the various stages of wound
healing may take several weeks to be
completed, our study focused on the ini-
tial events taking place in the first days
after wounding. Thus, to get a compre-
hensive view on the role of PARylation
in the complete wound-healing process,
we should also consider factors such as
angiogenesis and remodeling. Of note,
PARP-1 has been shown to be required
for both angiogenesis (38–40) and fibro-
sis (41). These observations may have
implications for the later stages of
wound healing, which might be worth
investigating.
Overall, our data presented here are in
line with the plethora of previous stud-
ies reporting the inflammation-promot-
ing and tissue-damage–mediator roles of
PARylation/PARP-1 as described in di-
verse biological models ranging from
various forms of shock, sepsis, ischemia-
reperfusion injury (13), arthritis (15),
contact hypersensitivity (42), experimen-
tal allergic encephalomyelitis (16) and
many others (13). Common features of
PARP inhibition/knockout in these in
vivo models include suppression of the
expression of inflammatory mediators,
reduced migration of inflammatory cells
to the site of inflammation, inhibition of
oxidative and nitrative stress and pre-
vention of cell dysfunction and cell
death. Some of these changes might also
be relevant in explaining our current
findings.
CONCLUSION
In summary, we report here that exci-
sion wounds heal faster if PARylation is
inhibited or PARP-1 gene is knocked out,
indicating that PARylation by PARP-1
delays wound healing. Owing to the
high complexity or regulatory circuitries
involved in wound healing, it is impossi-
ble to trace the effect of PARylation and
PARP-1 on wound healing to a single
molecular event. On the basis of our cur-
rent data, reduced expression of inflam-
matory mediators with special regard to
TNF-α, IL-1β and iNOS, suppressed ni-
trative stress and accelerated ker-
atinocyte migration may be the key ele-
ments underlying accelerated wound
healing in PARP-1-deficient animals or in
mice treated with PARP inhibitors.
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